drugset
drugset / Trial / NCT06933069

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

NCT06933069 ↗

Phase 1 Recruiting 55 enrolled Taizhou Mabtech Pharmaceutical Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.

Timeline

Start
2025-06-09
Primary completion
2026-05-31
Completion
2026-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject CMAB017 Unknown 100 mg Intravenous

Indications

cancer